Literature DB >> 10860577

HLA-DQ polymorphism influences progression of demyelination and neurologic deficits in a viral model of multiple sclerosis.

K D Pavelko1, K M Drescher, D B McGavern, C S David, M Rodriguez.   

Abstract

The importance of genetic susceptibility in determining the progression of demyelination and neurologic deficits is a major focus in neuroscience. We studied the influence of human leukocyte antigen (HLA)-DQ polymorphisms on disease course and neurologic impairment in virus-induced demyelination. HLA-DQ6 or DQ8 was inserted as a transgene into mice lacking endogenous expression of MHC class I (beta(2)m) and class II (H2-A(beta)) molecules. Following Theiler's murine encephalomyelitis virus (TMEV) infection, we assessed survival, virus persistence, demyelination, and clinical disease. Mice lacking expression of endogenous class I and class II molecules (beta(2)m(o) Abeta(o) mice) died 3 to 4 weeks postinfection (p.i.) due to overwhelming virus replication in neurons. beta(2)m(o) Abeta(o) DQ6 and beta(2)m(o) Abeta(o) DQ8 mice had increased survival and decreased gray matter disease and virus replication compared to nontransgenic littermate controls. Both beta(2)m(o) Abeta(o) DQ6 and beta(2)m(o) Abeta(o) DQ8 mice developed chronic virus persistence in glial cells of the white matter of the spinal cord, with greater numbers of virus antigen-positive cells in beta(2)m(o) Abeta(o) DQ8 than in beta(2)m(o) Abeta(o) DQ6 mice. At day 45 p.i., the demyelinating lesions in the spinal cord of beta(2)m(o) Abeta(o) DQ8 were larger than those in the beta(2)m(o) Abeta(o) DQ6 mice. Earlier and more profound neurologic deficits were observed in beta(2)m(o) Abeta (o) DQ8 mice compared to beta(2)m(o) Abeta(o) DQ6 mice, although by 120 days p.i. both strains of mice showed similar extent of demyelination and neurologic deficits. Delayed-type hypersensitivity and antibody responses to TMEV demonstrated that the mice mounted class II-mediated cellular and humoral immune responses. The results are consistent with the hypothesis that rates of progression of demyelination and neurologic deficits are related to the differential ability of DQ6 and DQ8 transgenes to modulate the immune response and control virus. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10860577      PMCID: PMC5450945          DOI: 10.1006/mcne.2000.0843

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  42 in total

1.  Clinical sub-groups of multiple sclerosis in relation to HLA: DR alleles as possible markers of disease progression.

Authors:  P Duquette; F Décary; J Pleines; D Boivin; G Lamoureux; J B Cosgrove; Y Lapierre
Journal:  Can J Neurol Sci       Date:  1985-05       Impact factor: 2.104

2.  Characterization of B lymphocytes present in the demyelinating lesions induced by Theiler's virus.

Authors:  E Cash; A Bandeira; S Chirinian; M Brahic
Journal:  J Immunol       Date:  1989-08-01       Impact factor: 5.422

3.  Could HLA-DRB1 be the protective locus in rheumatoid arthritis?

Authors:  E Zanelli; M A Gonzalez-Gay; C S David
Journal:  Immunol Today       Date:  1995-06

4.  Abrogation of resistance to Theiler's virus-induced demyelination in H-2b mice deficient in beta 2-microglobulin.

Authors:  M Rodriguez; A J Dunkel; R L Thiemann; J Leibowitz; M Zijlstra; R Jaenisch
Journal:  J Immunol       Date:  1993-07-01       Impact factor: 5.422

5.  Partial suppression of Theiler's virus-induced demyelination in vivo by administration of monoclonal antibodies to immune-response gene products (Ia antigens).

Authors:  M Rodriguez; W P Lafuse; J Leibowitz; C S David
Journal:  Neurology       Date:  1986-07       Impact factor: 9.910

6.  Major histocompatibility complex class II alleles and the course and outcome of MS: a population-based study.

Authors:  B G Weinshenker; P Santrach; A S Bissonet; S K McDonnell; D Schaid; S B Moore; M Rodriguez
Journal:  Neurology       Date:  1998-09       Impact factor: 9.910

7.  Ultrastructural immunohistochemical localization of virus in acute and chronic demyelinating Theiler's virus infection.

Authors:  M C Dal Canto; H L Lipton
Journal:  Am J Pathol       Date:  1982-01       Impact factor: 4.307

8.  Demyelination induced by Theiler's virus: influence of the H-2 haplotype.

Authors:  M Rodriguez; C S David
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

9.  Persistent infection of oligodendrocytes in Theiler's virus-induced encephalomyelitis.

Authors:  M Rodriguez; J L Leibowitz; P W Lampert
Journal:  Ann Neurol       Date:  1983-04       Impact factor: 10.422

Review 10.  Molecular mimicry and immune-mediated diseases.

Authors:  M B Oldstone
Journal:  FASEB J       Date:  1998-10       Impact factor: 5.191

View more
  5 in total

1.  Direct comparison of demyelinating disease induced by the Daniel's strain and BeAn strain of Theiler's murine encephalomyelitis virus.

Authors:  Laurie J Zoecklein; Kevin D Pavelko; Jeff Gamez; Louisa Papke; Dorian B McGavern; Daren R Ure; M Kariuki Njenga; Aaron J Johnson; Shunya Nakane; Moses Rodriguez
Journal:  Brain Pathol       Date:  2003-07       Impact factor: 6.508

2.  Transgenic expression of the 3D polymerase inhibits Theiler's virus infection and demyelination.

Authors:  Jason Kerkvliet; Laurie Zoecklein; Louisa Papke; Aleksandar Denic; Allan J Bieber; Larry R Pease; Chella S David; Moses Rodriguez
Journal:  J Virol       Date:  2009-09-16       Impact factor: 5.103

3.  Human HLA-DR transgenes protect mice from fatal virus-induced encephalomyelitis and chronic demyelination.

Authors:  Moses Rodriguez; Laurie Zoecklein; Jason G Kerkvliet; Kevin D Pavelko; Louisa Papke; Charles L Howe; Larry R Pease; Chella David
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

4.  An elite controller of picornavirus infection targets an epitope that is resistant to immune escape.

Authors:  Michael P Bell; Danielle N Renner; Aaron J Johnson; Kevin D Pavelko
Journal:  PLoS One       Date:  2014-04-07       Impact factor: 3.240

5.  Human class I major histocompatibility complex alleles determine central nervous system injury versus repair.

Authors:  Bharath Wootla; Aleksandar Denic; Jens O Watzlawik; Arthur E Warrington; Laurie J Zoecklein; Louisa M Papke-Norton; Chella David; Moses Rodriguez
Journal:  J Neuroinflammation       Date:  2016-11-17       Impact factor: 8.322

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.